



# THROMBOLUX

QUALITY REASSURANCE

**Significantly reducing the number of transfusions for the patients who need it most.**


---

Meta-analysis of the impact of activated transfusions on subsequent number of transfusions.<sup>1</sup>



# Transfusing activated platelets leads to an increase in transfusion requirements

Meta-analysis of the data from studies conducted at four hospitals consistently showed that prophylactic transfusions of activated platelets led to more transfusions than in patients who only received resting platelets. Reducing platelet variability is key to positively impacting clinical outcomes in the most vulnerable patients, those with cancer.



## OBJECTIVE

The objective was to combine data collected in four studies to investigate the impact of receiving a transfusion of activated platelets on the subsequent number of transfusions received by a hematology-oncology patient.



## OUTCOME


Among De Novo patients, the results of the combined data analysis showed that patients who received a transfusion of activated platelets typically required 4 transfusions more than patients who only received transfusions of resting platelets ( $p < 0.001$ ). Patients who received a transfusion of activated platelets typically require 6 subsequent transfusions compared to 2 subsequent transfusions for matched patients receiving transfusions of resting platelets.

**On average, the transfusion of activated platelets increased the subsequent transfusion requirement by four transfusions.**



# 471 Patients

who had no prior documented platelet transfusions (De Novo Patients) were included in the analysis.



The Right Product. The Right Patient. Right Now.

## EQUALS 4 LESS TRANSFUSIONS

A patient transfused with activated platelets **required more transfusions** compared to patients receiving resting platelets.

Median # Transfusions Post- Activated

STUDY	ACTIVATED	MATCHING RESTING	MEDIAN EXCESS TRANSFUSIONS*	P-VALUE
Overall	6	2	4	<0.001
Canadian Hospital	4	2	2	0.0070
US Hospital 1	7	2	5	0.0016
US Hospital 2	9	2	7	<0.001
US Children's Hospital	5	1	4	<0.001

\*95% Confidence interval


# Allocating the right platelets to the right patients helps make the most of a precious commodity



**Resting platelets** retain their discoid shape and are lifesaving for the most vulnerable patients—those with cancer.

## Potential impact of resting platelets on cancer patients

- Significantly reduced number of transfusions
- Reduced chance of immune refractoriness



**Activated platelets** have changed to an amorphous form through normal processes and are ideal for cold storage and use in trauma patients.

## Potential impact of activated platelets on cancer patients

- Reduced platelet count increments, increasing the need for more infusions
- Increased chance of refractoriness due to increased number of infusions
- May interfere with certain immunotherapies, complicating treatment

**Identifying and distributing platelet products based on activation status can result in improved patient outcomes and cost savings<sup>2</sup>**

The ThromboLUX System lets you assess activation status right when you get the product. Quickly. Safely. Definitively.

**It's time to take control over platelet variability with ThromboLUX. For more information or to read the full study, please visit:**

**THROMBOLUX.COM**